<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. )*
-----
Aastrom Biosciences, Inc.
-------------------------------------------------------------
(Name of Issuer)
Common Stock
---------------------------------------------------
(Title of Class of Securities)
00253U107
-----------------------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 5 Pages
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 00253U107 13G PAGE 2 OF 5 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
COBE Laboratories, Inc.
95-2403584
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4
Colorado
- ------------------------------------------------------------------------------
SOLE VOTING POWER
5
NUMBER OF 3,214,199
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 6
0
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
7
REPORTING 3,214,199
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 8
0
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9
3,214,199
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
10
[_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11
24.2%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
12
CO
- ------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
Page 3 of 5 Pages
Item 1.
(a) Name of Issuer:
--------------
Aastrom Biosciences, Inc. ("Aastrom")
(b) Address of Issuer's Principal Executive Offices:
-----------------------------------------------
24 Frank Lloyd Wright Drive, Lobby L
P. O. Box 376
Ann Arbor, MI 48106
Item 2.
(a) Name of Person Filing:
---------------------
COBE Laboratories, Inc. ("COBE")
(b) Address of Principal Business Office:
------------------------------------
1185 Oak Street
Lakewood, CO 80215
(c) Citizenship:
-----------
Colorado
(d) Title of Class of Securities:
----------------------------
Common Stock, no par value per share
(e) CUSIP Number:
------------
00253U107
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b),
check whether the person filing is a:
(a) ( ) Broker or dealer registered under Section 15 of the Act,
(b) ( ) Bank as defined in Section 3(a)(6) of the Act,
(c) ( ) Insurance Company as defined in Section 3(a)(19) of the
Act,
(d) ( ) Investment Company registered under Section 8 of the
Investment Company Act,
<PAGE>
Page 4 of 5 Pages
(e) ( ) Investment Adviser registered under Section 203 of the
Investment Advisers Act of 1940,
(f) ( ) Employee Benefit Plan, Pension Fund which is subject to
the provisions of the Employee Retirement Income
Security Act of 1974 or Endowment Fund; see Rule 13d-
1(b)(1)(ii)(F),
(g) ( ) Parent Holding Company, in accordance with Rule
13d-1(b)(1)(ii)(G), or
(h) ( ) Group, in accordance with Rule 13d-1(b)(1)(ii)(H)
Item 4. Ownership.
---------
(a) Amount Beneficially Owned:
3,214,199
(b) Percent of Class:
24.2%. Based on 13,278,983 shares issued and outstanding as
verified by a telephone call to Continental Transfer Company.
(c) Number of shares as to which such person has sole or shared
voting and disposition power:
3,214,199
Item 5. Ownership of Five Percent or Less of a Class.
--------------------------------------------
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial owner
of more than five percent of the class of securities, check the
following ( ).
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
---------------------------------------------------------------
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired
------------------------------------------------------------------
the Security Being Reported on by the Parent Holding Company.
------------------------------------------------------------
Not applicable.
<PAGE>
Page 5 of 5 Pages
Item 8. Identification and Classification of Members of the Group.
---------------------------------------------------------
Not applicable.
Item 9. Notice of Dissolution of Group.
------------------------------
Not applicable.
Item 10. Certification.
-------------
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired in the ordinary
course of business and were not acquired for the purpose of and do not
have the effect of changing or influencing the control of the issuer
of such securities and were not acquired in connection with or as a
participant in any transaction having such purpose or effect.
Signature.
----------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth is this statement is true, complete and
correct.
COBE LABORATORIES, INC.
Date: January 28, 1998 By /s/ NANCY A. WALLA
----------------------------
Nancy A. Walla
Vice President/Counsel
Corporate Compliance